Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

In the first direct comparison study involving individuals with obesity, tirzepatide demonstrated approximately 50% greater ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro and Zepbound) lost more weight and inches from their waist than those who ...

GLP-1 medications like semaglutide and tirzepatide have exploded in popularity, with millions of Americans turning to them for weight loss. But are they the magic bullet for sustainable results? The ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...